amifostine + azacitidine

Amifostine + azacitidine is an investigational combination therapy consisting of two distinct agents: - Amifostine is a cytoprotective agent, a prodrug that is dephosphorylated in tissues to an active free thiol metabolite. It protects normal (non-cancerous) cells from the toxic effects of chemotherapy and radiation by scavenging free radicals and donating hydrogen ions, thereby reducing DNA damage in healthy tissue. It does not protect tumor cells to the same extent due to lower uptake and activation in malignant tissue. - Azacitidine is a nucleoside metabolic inhibitor classified as a hypomethylating agent. It incorporates into DNA and RNA, inhibiting DNA methyltransferase, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The combination has been studied primarily for its potential use in myelodysplastic syndromes (MDS), with amifostine administered alongside azacitidine to reduce treatment-related toxicities while maintaining or enhancing antitumor efficacy[1][2][4]. The rationale for this combination is that amifostine may mitigate some adverse effects associated with azacitidine-based regimens without compromising their therapeutic activity.

Other names

amifostine + azacitidine